Regulation of endothelin-converting enzyme-1 expression in human neuroblastoma cells.
In recent years endothelin-converting enzyme (ECE-1) has been suggested to play an important role in amyloid-beta peptide metabolism as one of the amyloid-degrading enzymes. In this connection, the analysis of the levels of expression and distribution of ECE-1 in the brain under normal and pathologic conditions could be important in neurodegeneration and pathogenesis of Alzheimer disease. In our previous studies, we have demonstrated that expression of ECE-1 was significantly reduced in the cortex of adult rats after 15 mins of global ischemia. It was also significantly reduced in the striatum of rats subjected to prenatal hypoxia. In the present study, we analyzed effects of hypoxia and oxidative stress on ECE-1 in human neuroblastoma NB7 cells and effects of the cholinergic agonist carbachol and the phorbol ester, phorbol 12-myristate 13-acetate (PMA). We have found that chronic (24 hrs) hypoxia and oxidative stress resulted in 30% and 20% decrease in expression of ECE-1 at the protein level, respectively, although at the level of ECE-1 mRNA there were no statistically significant changes. Serum withdrawal from the incubation medium as well as addition of carbachol or PMA for 24 hrs also led to a significant reduction of the levels of ECE-1 protein in NB7 cells. Further study of the downstream signaling cascades involved in downregulation of ECE expression in NB7 cells and primary neuronal cells might provide us with new insights into possible therapeutic strategies for prevention or treatment of Alzheimer disease in elderly patients and those who suffer from stroke or cerebrovascular disorders.
Fisk
Lilia
L
Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, Mount Preston Street, University of Leeds, Leeds LS2 9JT, United Kingdom.
Nalivaeva
Natalia N
NN
Turner
Anthony J
AJ
D016282:Aspartic Acid Endopeptidases / Q000235:genetics / Q000378:metabolism*; D002217:Carbachol / Q000494:pharmacology; D015687:Cell Hypoxia; D045744:Cell Line, Tumor; D018679:Cholinergic Agonists / Q000494:pharmacology; D000072396:Endothelin-Converting Enzymes; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D051272:Glucose Transporter Type 1 / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006861:Hydrogen Peroxide / Q000494:pharmacology; D008666:Metalloendopeptidases / Q000235:genetics / Q000378:metabolism*; D009447:Neuroblastoma / Q000378:metabolism* / Q000473:pathology*; D016877:Oxidants / Q000494:pharmacology; D018384:Oxidative Stress; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D018679:Cholinergic Agonists; D051272:Glucose Transporter Type 1; D016877:Oxidants; C495677:SLC2A1 protein, human; D002217:Carbachol; D006861:Hydrogen Peroxide; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606923:ECE1 protein, human; D000072396:Endothelin-Converting Enzymes; D013755:Tetradecanoylphorbol Acetate